1 Surprising Reason Alzheimer's Drugs Remain So Elusive

1 Surprising Reason Alzheimer's Drugs Remain So Elusive

Source: 
Motley Fool
snippet: 

When Biogen (NASDAQ: BIIB) and Eisai announced their decision to pull the plug on a late-stage trial for aducanumab in treating Alzheimer's disease, it was just the latest in a long string of failures for experimental treatments targeting the neurodegenerative disease. The failure looks like the last nail in the coffin for the amyloid hypothesis, which postulates that the accumulation of beta-amyloid proteins in brain cells is the root cause of the disease.